15.12.2020

EVER PHARMA GAINS EU MARKETING AUTHORIZATION FOR VALUE-ADDED PEMETREXED

EVER Pharma is pleased to announce EU-wide marketing authorization of Pemetrexed for the treatment of patients with Malignant pleural mesothelioma and Non-small cell lung cancer1.

Pemetrexed EVER Pharma is formulated as a liquid which has several advantages over the innovator powder product from Lilly. The liquid formulation does not require reconstitution prior to preparing a patient specific dose meaning safer handling, and savings in time and costs, especially where multiple vials are required.

Unlike other liquid formulations, the EVER product can be conveniently stored at room temperature and does not take up valuable refrigerated storage space. The product comes in 100 mg and 500 mg vials, and a new 1000 mg presentation targeted at larger patient doses thereby reducing the costly wastage of left-over product after the patient dose is extracted.

The use of Pemetrexed is growing widely around the world making it one of the very critical medications in cancer therapy.

“We are pleased to be able to provide another innovative EVER product that enhances safe and efficient patient dose preparation and has the potential to meaningfully improve access to this treatment for the cancer patients” said Georges Kahwati, General Manager of Ever Pharma.

The European authorization of EVER Pharma’s Pemetrexed quickly follows the recent European registration of its Cabazitaxel. Both products are planned for roll out into major markets globally.

1. Pemetrexed EVER Pharma is indicated: (i) in combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma, (ii) as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy, (iii) as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.